AOD-9604

Tyr-hGH (177–191); modified hGH C-terminal fragment

Identity

Sequence

YLRIVQCRSVEGSCGF (C7–C14 disulfide)

Three-letter

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe; Cys⁷–Cys¹⁴ disulfide

Length

16 residues

Modifications

N-terminal Tyr addition; intramolecular disulfide

Formula

C78H123N23O23S2

Average mass

1815.1 Da

CAS

221231-10-3

Specifications (per released lot)

Purity

≥ 98 % by RP-HPLC, 220 nm

Identity

ESI-MS; observed mass within 0.1 % of calculated

Form

White to off-white lyophilized powder

Counter-ion

Trifluoroacetate; acetate on request

Net peptide content

Reported per lot (typically 70–90 % of gross mass; the balance is counter-ion and water)

Vial sizes

5 mg · 10 mg · 25 mg net peptide; bulk on quotation

Storage

−20 °C, desiccated, protected from light. Ships at ambient temperature.

Documents

Lot certificate of analysis (COA library); safety data sheet in WHMIS 2015 format, enclosed with every shipment

Research context

Modified C-terminal fragment of human growth hormone (residues 177–191 with an added N-terminal tyrosine). Used in lipid-metabolism and adipocyte research.

Literature context is provided to help laboratories identify the reagent. It is not a claim about effects in people and does not describe any use outside in-vitro or approved animal research.